Evidence map›Paper›PMID 35690720›Full record

Trial reportJournal of neurodevelopmental disorders2022

An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities.

Isabella Slaby, Heather S Hain, Debra Abrams, Frank D Mentch, Joseph T Glessner, Patrick M A Sleiman, Hakon Hakonarson

4 registry-linked trialsOpen access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase IIClinical Trial, Phase III
In one paragraph

Trial report in Journal of neurodevelopmental disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02286817 phase1completednot on this map

Phase I Single Dose, Open-label, Pharmacokinetic Study Followed by Single-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Plasma Concentration Profiles, and Targeted Efficacy of NFC-1 in Adolescents (12-17 Years of Age) With Attention-Deficit Hyperactivity Disorder and Genetic Disruption Impacting Metabotropic Glutamate Receptor Genes (NFC1-GREAT)

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2015 to 2016Enrolled30ConditionsAttention-deficit Hyperactivity Disorder (ADHD)ArmsNFC-1
NCT02777931 phase2 / phase3completednot on this map

A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2016 to 2017Enrolled101ConditionsAttention Deficit Disorder With HyperactivityArmsNFC-1, Placebo
NCT02895906 phase1completednot on this map

A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2016 to 2017Enrolled2Conditions22q11.2 Deletion SyndromeArmsNFC-1
NCT03006367 phase1completednot on this map

An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2017 to 2017Enrolled32ConditionsAttention Deficit Disorder With HyperactivityArmsNFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Adjuvant Therapy for Attention in Children with ADHD Using Game-Type Digital Therapy.International journal of environmental research and public health · 2022
    Article
  15. Phenotyping in distributed data networks: selecting the right codes for the right patients.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Isabella SlabyThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Heather S HainThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Debra AbramsThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Frank D MentchThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Joseph T GlessnerThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.ORCID 0000-0001-5131-2811
Patrick M A SleimanThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Hakon HakonarsonThe Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. hakonarson@chop.edu.
Children's Hospital of Philadelphia · US

Funding

Integrative Analysis of a GWAS Repository with EMRs from over 40,000 ChildrenU01HG006830 · NHGRI · CHILDREN'S HOSP OF PHILADELPHIA · PI HAKONARSON, HAKON · 2012 to 2014
$3.7M
NHGRI NIH HHS U01 HG006830NHGRI NIH HHS U01-HG006830
6 · The paper itself

Abstract

backgroundIn over half of pediatric cases, ADHD presents with comorbidities, and often, it is unclear whether the symptoms causing impairment are due to the comorbidity or the underlying ADHD. Comorbid conditions increase the likelihood for a more severe and persistent course and complicate treatment decisions. Therefore, it is highly important to establish an algorithm that identifies ADHD and comorbidities in order to improve research on ADHD using biorepository and other electronic record data.

methodsIt is feasible to accurately distinguish between ADHD in isolation from ADHD with comorbidities using an electronic algorithm designed to include other psychiatric disorders. We sought to develop an EHR phenotype algorithm to discriminate cases with ADHD in isolation from cases with ADHD with comorbidities more effectively for efficient future searches in large biorepositories. We developed a multi-source algorithm allowing for a more complete view of the patient's EHR, leveraging the biobank of the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP). We mined EHRs from 2009 to 2016 using International Statistical Classification of Diseases and Related Health Problems (ICD) codes, medication history and keywords specific to ADHD, and comorbid psychiatric disorders to facilitate genotype-phenotype correlation efforts. Chart abstractions and behavioral surveys added evidence in support of the psychiatric diagnoses. Most notably, the algorithm did not exclude other psychiatric disorders, as is the case in many previous algorithms. Controls lacked psychiatric and other neurological disorders. Participants enrolled in various CAG studies at CHOP and completed a broad informed consent, including consent for prospective analyses of EHRs. We created and validated an EHR-based algorithm to classify ADHD and comorbid psychiatric status in a pediatric healthcare network to be used in future genetic analyses and discovery-based studies.

resultsIn this retrospective case-control study that included data from 51,293 subjects, 5840 ADHD cases were discovered of which 46.1% had ADHD alone and 53.9% had ADHD with psychiatric comorbidities. Our primary study outcome was to examine whether the algorithm could identify and distinguish ADHD exclusive cases from ADHD comorbid cases. The results indicate ICD codes coupled with medication searches revealed the most cases. We discovered ADHD-related keywords did not increase yield. However, we found including ADHD-specific medications increased our number of cases by 21%. Positive predictive values (PPVs) were 95% for ADHD cases and 93% for controls.

conclusionWe established a new algorithm and demonstrated the feasibility of the electronic algorithm approach to accurately diagnose ADHD and comorbid conditions, verifying the efficiency of our large biorepository for further genetic discovery-based analyses.

trial registrationClinicalTrials.gov, NCT02286817 . First posted on 10 November 2014. CLINICALTRIALS: gov, NCT02777931 . First posted on 19 May 2016. CLINICALTRIALS: gov, NCT03006367 . First posted on 30 December 2016. CLINICALTRIALS: gov, NCT02895906 . First posted on 12 September 2016.

Indexed as

Attention Deficit Disorder with HyperactivityAlgorithmsCase-Control StudiesChildComorbidityElectronic Health RecordsHumansPhenotypeProspective StudiesRetrospective Studies

Identifiers

PMID35690720
PMCPMC9188139
OpenAlexW4282935799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.